Business Context and Reporting Period
This Form 8-K Current Report was filed by LifeStance Health Group, Inc. on February 25, 2026, with the closing of the described transaction occurring on March 2, 2026. The filing details a secondary offering of the Company's common stock.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The transaction described is a secondary offering where the Company did not receive any proceeds.
- Shares Offered: 25,000,000 shares of Common Stock.
- Sellers: Selling Stockholders (not the Company).
- Company Proceeds: $0.
- Company Repurchase: The Company agreed to purchase 7,000,000 of the shares sold by the Selling Stockholders at the same price paid by the Underwriter.
- Underwriter Compensation: The Underwriter (J.P. Morgan Securities LLC) received no compensation for the shares repurchased by the Company.
Material Changes
The primary material event is the execution of an Underwriting Agreement for a secondary offering. This results in a change in the ownership structure of the Company's common stock, with 25,000,000 shares moving from Selling Stockholders to the public market. The Company's capitalization is affected by the repurchase of 7,000,000 shares, though the filing text does not specify the purchase price or the total cash outflow for this repurchase.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not explicitly list new risks or contingencies beyond the standard disclosure that the description of the Underwriting Agreement is qualified by its full terms. The transaction is a routine secondary offering mechanism.
Investor Verification Checklist
- Verify the specific price per share paid by the Underwriter to determine the total cost of the 7,000,000 share repurchase by the Company.
- Confirm the identity of the Selling Stockholders to assess potential dilution or insider selling pressure.
- Review the full Underwriting Agreement (Exhibit 1.1) for any lock-up agreements or additional covenants.
- Check subsequent filings for the impact of the share repurchase on the Company's cash position and balance sheet.